Clinical Trials Logo

Stage II Bladder Cancer AJCC v8 clinical trials

View clinical trials related to Stage II Bladder Cancer AJCC v8.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04501913 Active, not recruiting - Malignant Neoplasm Clinical Trials

Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes

Start date: December 24, 2019
Phase:
Study type: Observational

This study examines at-home monitoring of patient-generated phsyiologic health data and patient-reported outcomes. Patient-generated health data using at-home monitoring devices and smart device applications are used more and more to measure value and quality in cancer care. This trial may show whether at-home monitoring programs can improve the care of patients after hospital discharge from surgery.

NCT ID: NCT03775265 Active, not recruiting - Clinical trials for Bladder Urothelial Carcinoma

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Start date: June 3, 2019
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as gemcitabine, cisplatin, fluorouracil and mitomycin-C, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with radiation therapy may kill more tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with radiation therapy and chemotherapy may work better in treating patients with localized muscle invasive bladder cancer compared to radiation therapy and chemotherapy without atezolizumab.